Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15, January 2008

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia

  • C. Daniel Mullins

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 410 706 0879; fax: +1 410 706 5394.
    • ,
  • Nour A. Obeidat

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Brian J. Cuffel

      Affiliations

    • Pfizer Inc, New York NY, United States
    • ,
  • John Naradzay

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Antony D. Loebel

      Affiliations

    • Pfizer Inc, New York NY, United States

Received 15 November 2006; received in revised form 25 April 2007; accepted 26 April 2007. published online 28 June 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0920-9964(07)00191-0

doi:10.1016/j.schres.2007.04.035

Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15, January 2008

Article Tools

* Image Usage & Resolution